COVID-19 Resources for the Pancreatic Cancer Patient: We are Behind you, Every Step of the Way
We are committed to assisting pancreatic cancer patients to find information during this challenging time with the COVID-19 pandemic. Below are some useful resources.
- Pancreatic Cancer Action: Coronavirus (COVID-19) Resource Center
- Pancreatic Cancer Action Network: Navigating Pancreatic Cancer Care During the Coronavirus Crisis
- Lustgarten Foundation for Pancreatic Research: What Pancreatic Cancer Patients Should Know About COVID-19
- Let’s Win Pancreatic Cancer: Pancreatic Cancer Treatment During the COVID-19 Pandemic
- American Society of Clinical Oncology
- ESMO Management and Treatment Adapted Recommendations in the COVID-19 Era: Pancreatic Cancer
Pancreatic cancer is on the rise. The number of cases of pancreatic cancer is also increasing globally. In 2018, approximately 460,000 new cases of pancreatic cancer were reported.
Although advances in cancer treatments continue to grow, there is still a great need for new therapies. Promising new treatment options and ways to deliver these treatments more effectively are now under development.
Do you have locally advanced pancreatic cancer that cannot be treated surgically and has not spread to other parts of your body?
- We are currently looking for men and women who have been diagnosed with pancreatic cancer who may be interested in joining a clinical research study called the TIGeR-PaC Study.
- The TIGeR-PaC Study is investigating a new way of administering chemotherapy in people with pancreatic cancer.
- If you qualify for the study, study medicine and all study-related care will be provided at no additional cost by your insurance or Company conducting the TIGeR-PaC Study.
- Participation in the TIGeR-PaC Study is voluntary, and you can leave the study at any time, for any reason.
Patient Stories
Watch news reports of real patients undergoing targeted diagnostic and therapeutic infusion using the RenovoCath, which is FDA cleared and now being investigated in an active clinical trial to prove extended median survival and improved quality of life.
RenovoRx on Twitter
Sarasota Herald-Tribune Features Positive Impact of the Phase III TIGeR-PaC Clinical Trial for Patient #pancreaticcancer #clinicaltrials
http://www.icontact-archive.com/archive?c=1773977&f=6180&s=6814&m=242952&t=6573b40293439f53ef02c273f2ec76f6840517684a6eb7328a7e3eb308e482f6
Studies that Further Advance the Science of Pancreatic Cancer Treatment Presented at the 2021 ASCO Gastrointestinal Cancers Symposium
http://www.icontact-archive.com/archive?c=1773977&f=6180&s=6814&m=223550&t=6573b40293439f53ef02c273f2ec76f6840517684a6eb7328a7e3eb308e482f6
Proud to share news of this important milestone with the enrollment of 100th patient in the phase III TIGeR-PaC clinical trial. https://renovorx.com/renovorx-continues-with-strong-momentum-and-reaches-milestone-of-100th-patient-enrolled-in-its-phase-iii-tiger-pac-clinical-trial/
Proud to share a news story from the Miami Herald regarding some recent patient experiences in the Phase III TIGeR-PaC Clinical Trial. https://www.miamiherald.com/news/nation-world/national/article246057105.html